China's GLP-1 Wave: Ecnoglutide, Semaglutide Copies and US Prices
China now has its own approved GLP-1 drugs, led by Innovent's mazdutide and Sciwind's ecnoglutide, which China approved for weight management in March 2026, plus a line of domestic semaglutide copies that are still waiting even though the patent expired in March 2026. None of this lowers US prices directly, because none of these products can be legally sold to or imported by US patients. The real US impact comes later, through licensing deals like Kailera's ribupatide, whose global Phase 3 results are expected in mid-2028.
Key takeaways
- Ecnoglutide was approved in China for type 2 diabetes in January 2026 and for chronic weight management in March 2026; Pfizer China holds commercial rights there.
- In its Phase 3 SLIMMER trial, ecnoglutide 2.4 mg produced 15.4% mean weight loss at 48 weeks (15.1% after subtracting placebo).
- China's semaglutide patent expired in March 2026, but Novo Nordisk says regulatory data protection runs until April 2027; no domestic copy had been confirmed as approved as of October 2026.
- Chinese-origin drugs reach the US only through FDA approval, typically after a US partner runs global trials. Ribupatide (from Hengrui) is the furthest along.
Why China's GLP-1 market matters
China went from importing every GLP-1 to approving homegrown ones in about a year. GlobalData projected China's obesity drug market growing from $2.181 billion in 2025 to $7.539 billion in 2030, and counted ten more domestic obesity drugs in Phase 3 (GlobalData via PharmaLive). Those are forecasts, but they explain why global companies keep signing Chinese obesity deals.
Price is part of the story. At launch, Goldman Sachs estimated monthly costs in China at maximum doses of about $400 for Wegovy and $900 for Mounjaro, and Innovent priced four 6 mg pens of mazdutide at 2,920 yuan, about $411 at the time (Reuters via Zawya).
Ecnoglutide: China's second homegrown obesity approval
Ecnoglutide (XW003) is a once-weekly GLP-1 receptor agonist from Hangzhou-based Sciwind Biosciences. Sciwind describes it as "cAMP-biased," meaning it is designed to favor one signaling pathway inside the cell while limiting another (β-arrestin) that is linked to receptor desensitization (Sciwind, January 2026). Whether that design produces a meaningful clinical advantage has not been shown in a head-to-head trial against semaglutide.
Approvals
- January 30, 2026: NMPA approval for glycemic control in adults with type 2 diabetes (Sciwind).
- February 24, 2026: Pfizer China gained exclusive commercialization rights in mainland China; Sciwind can receive up to $495 million in payments and remains the license holder and manufacturer (Sciwind).
- March 6, 2026: NMPA approval for chronic weight management in adults with overweight or obesity (Sciwind).
The trial data
| Trial | Population | Main result |
|---|---|---|
| SLIMMER (Phase 3, 48 weeks) | 664 Chinese adults with overweight or obesity | 2.4 mg: −15.4% weight (−15.1% placebo-adjusted); 79.6% lost at least 10%, 63.5% at least 15% |
| EECOH-1 (Phase 3, 24 weeks) | 211 adults with type 2 diabetes, monotherapy | 1.2 mg: HbA1c −2.43%; 80.3% reached HbA1c under 7%; weight −4.74% |
| EECOH-2 (Phase 3, 52 weeks) | Type 2 diabetes on metformin | 0.6 mg: HbA1c −1.91% at week 32; both doses beat dulaglutide 1.5 mg on HbA1c target rates at week 52 |
Sources: Sciwind releases on SLIMMER, the obesity approval, EECOH-1 and the diabetes approval. SLIMMER was published in The Lancet Diabetes & Endocrinology.
Sciwind also reported a 53.1% average reduction in liver fat at week 40 in SLIMMER participants with elevated baseline liver fat. These are company-reported figures from Chinese populations, and the obesity results come from one Phase 3 trial.
Mazdutide and ribupatide: the dual agonists
Mazdutide, a GLP-1/glucagon drug that Innovent developed for China under license from Lilly, opened this wave with its weight-management approval in June 2025 (Fierce Pharma).
Jiangsu Hengrui's GLP-1/GIP dual agonist is the one most likely to reach the US. Kailera Therapeutics licensed exclusive rights outside Greater China in May 2024 and calls it ribupatide (KAI-9531). Kailera's September 30, 2026 release said Hengrui has submitted an application to China's NMPA for long-term weight management (Kailera). In a Chinese Phase 2 trial, the 8 mg weekly dose produced 23.6% weight loss at 36 weeks versus 1.7% on placebo (Kailera).
These drugs aren't sold in the US
If you need treatment now, compare the FDA-approved GLP-1 options available today.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Domestic semaglutide copies in China
Novo Nordisk's semaglutide patent in China was set to expire in 2026, and Reuters reported that CSPC Pharmaceutical Group and Hangzhou Jiuyuan Genetic Biopharmaceutical were among the companies developing versions. Macquarie analysts expected generic semaglutide in China in 2027, or as early as 2026 (Reuters via Zawya).
Two complications are worth knowing. First, the patent did lapse in March 2026, but Novo told Bloomberg in May 2026 that Ozempic is entitled to regulatory data protection in China until April 2027 under the China–Switzerland Free Trade Agreement. Jiuyuan, the first Chinese applicant, said its review had been suspended because of data protection provisions (Bloomberg via Swissinfo). Second, no NMPA or company announcement confirming an approved domestic semaglutide had appeared as of October 2026. If you see a specific approval claim, check it against the company's own announcement.
Are copies the same as Ozempic?
Not automatically. Novo makes semaglutide with recombinant (biological) methods, while many generic makers use chemical synthesis. Brazil's regulator, Anvisa, explained in March 2026 that it reviews synthetic copies closely for unwanted immune reactions, such as anti-drug antibodies that can make semaglutide ineffective for a patient (Agência Brasil). Brazil has since approved several synthetic versions after that review, including its first generic in August 2026 (Agência Brasil). China's regulator applies its own standards, and an approval in one country says nothing about whether the product would meet FDA requirements.
| Drug | Developer | Type | China status (Oct 2026) | US status |
|---|---|---|---|---|
| Mazdutide (Xinermei) | Innovent (from Lilly) | GLP-1/glucagon | Approved: obesity, type 2 diabetes | Not approved; Lilly holds ex-China rights |
| Ecnoglutide | Sciwind (Pfizer China sells) | Biased GLP-1 | Approved: type 2 diabetes, weight management | Not approved |
| Ribupatide (KAI-9531) | Hengrui (Kailera ex-China) | GLP-1/GIP | Application submitted for weight management | Global Phase 3 enrolled; topline expected mid-2028 |
| Semaglutide copies | CSPC, Jiuyuan and others | GLP-1 (copy of Novo's molecule) | Patent expired March 2026; Novo cites data protection to April 2027; no approval confirmed | Cannot be sold while US patents and FDA rules apply |
Sources: Fierce Pharma, Sciwind, Kailera, Reuters via Zawya, Bloomberg via Swissinfo.
What it means for US prices
1. No direct effect today
A lower price in Beijing does not change what a US pharmacy charges. Drugs must be FDA approved to be sold here, and the FDA's personal importation guidance is blunt: "If a drug is approved for use in another country but is an unapproved new drug in the U.S. it is illegal to import." That covers mazdutide, ecnoglutide and Chinese-made semaglutide alike.
2. Competition arrives through licensing, slowly
The realistic path is a US or global partner running trials for the FDA. Ribupatide is the clearest case. Kailera's KaiNETIC Phase 3 program completed enrollment of three trials (about 2,500, 1,200 and 1,200 people) at more than 200 sites in 11 countries, including KaiNETIC-3, which compares ribupatide with semaglutide 2.4 mg in people with a BMI of 35 or higher. Kailera expects topline data from all three trials in mid-2028 (Kailera). A US approval would come after that.
Deal flow keeps growing. In October 2026, Roche agreed to a deal worth up to $1.16 billion with China's Rona Therapeutics for an obesity drug targeting ALK7, a different mechanism from GLP-1 (Fierce Pharma Asia). More competitors in development is generally good for future prices, but none of it changes what you pay in 2026.
3. Chinese semaglutide copies won't reach US pharmacies before US patents expire
US generic semaglutide timing depends on US patents and FDA approval of generic applications, not on what happens in China. We cover that timeline in our separate patent cliff article.
The bottom line
China's GLP-1 wave is real: two homegrown approvals for weight management, a third application pending, and semaglutide copies queued behind data protection that Novo says lasts until April 2027. For US patients, it is a preview of future competition rather than a source of cheaper medicine today. If cost is your barrier now, talk to your prescriber about FDA-approved options and manufacturer or insurance programs.
Looking for a lower price now?
See what FDA-approved GLP-1 treatment costs from providers today.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Frequently asked questions
Is ecnoglutide approved?
Yes, in China only. The NMPA approved ecnoglutide for type 2 diabetes in January 2026 and for chronic weight management in March 2026. It is not FDA approved.
How much weight loss did ecnoglutide produce?
In the 48-week Phase 3 SLIMMER trial in 664 Chinese adults, the 2.4 mg dose produced 15.4% mean weight loss, or 15.1% after subtracting placebo.
Will cheaper Chinese GLP-1s lower US prices?
Not directly. Drugs approved only in China are illegal to import into the US, so lower Chinese prices don't change US pharmacy prices. Competition could arrive later through licensed drugs like ribupatide, whose global Phase 3 results are expected in mid-2028.
Can I buy Chinese generic semaglutide online?
Not legally. The FDA says a drug approved in another country but unapproved in the US is illegal to import, and it warns that GLP-1 products sold online may contain the wrong ingredients.
Sources
- Sciwind: Ecnoglutide approved by NMPA for type 2 diabetes (January 30, 2026)
- Sciwind: Partnership with Pfizer China (February 24, 2026)
- Sciwind: Ecnoglutide approved for chronic weight management (March 6, 2026)
- Sciwind: SLIMMER Phase 3 results published in The Lancet Diabetes & Endocrinology
- Sciwind: EECOH-1 Phase 3 results in Nature Communications
- Reuters via Zawya: Innovent's weight-loss drug highlights China challenge for Novo, Lilly
- GlobalData via PharmaLive: China's obesity market poised for takeoff
- Fierce Pharma: With China approval, mazdutide breaks into new class
- Kailera: Completion of enrollment in KaiNETIC Phase 3 (September 30, 2026)
- Kailera: Ribupatide
- Fierce Pharma Asia: Roche obesity deal with Rona
- Bloomberg via Swissinfo: Novo sees generic Ozempic delayed in China until next year (May 6, 2026)
- Agência Brasil: Anvisa aprova novas canetas de semaglutida, incluindo a 1ª genérica (August 17, 2026)
- Agência Brasil: Patente da semaglutida cai nesta sexta-feira (Anvisa on synthetic semaglutide)
- FDA: Personal importation
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss
Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.